Select Page

Crawford Investment Counsel Inc. decided to trim its holdings in Cardinal Health, Inc. (NYSE:CAH) by a modest 0.3% during the first quarter, as revealed in its recent filing with the Securities & Exchange Commission. As a result of this move, the institutional investor’s ownership stood at 757,320 shares of the company’s stock, having sold 2,378 shares during this period. This translated to Crawford Investment Counsel Inc. owning 0.30% of Cardinal Health, valued at approximately $57,178,000 by the close of the most recent quarter.

It’s worth noting that several other institutional investors and hedge funds have also entered and exited positions in CAH. Delta Asset Management LLC TN, for instance, initiated a new position in Cardinal Health during the fourth quarter, with an estimated value of around $25,000. Similarly, Benjamin Edwards Inc. made a fresh entry into Cardinal Health’s shares during the first quarter, amounting to approximately $27,000.

The Retirement Group LLC, not to be left out, significantly bolstered its position in Cardinal Health during the fourth quarter by a staggering 1,539.3%. Their current holdings comprise 459 shares of the company’s stock, valued at $35,000, which includes an additional purchase of 431 shares in the last quarter. GPS Wealth Strategies Group LLC also joined the fray, acquiring a new position in Cardinal Health during the first quarter, with an approximate value of $38,000. Last but not least, Tradition Wealth Management LLC followed suit during the first quarter, expanding their stake in Cardinal Health by 78.3%. Presently, they hold 535 shares of the company’s stock, valued at $40,000, including the purchase of an additional 235 shares in the last quarter. When it comes to ownership, institutional investors collectively hold a whopping 86.01% of Cardinal Health’s stock.

In terms of analyst opinions, CAH has been the subject of numerous research reports. Morgan Stanley, for instance, notched up their price target on Cardinal Health from $92.00 to $100.00 while endorsing the company with an “overweight” rating in a research report dated August 16th. Barclays was also in the mix, bumping up their price target on Cardinal Health from $80.00 to $85.00 in a report issued on June 9th. Meanwhile, Robert W. Baird was even more optimistic, elevating their price target from $107.00 to $108.00 and bestowing upon the company an “outperform” rating in an August 16th research note.

Adding to the chorus of opinions, StockNews.com initiated coverage on Cardinal Health on August 17th, awarding the company a “strong-buy” rating. Finally, Bank of America was in agreement with others, elevating their target price on Cardinal Health from $91.00 to $99.00 in a report on July 17th. As it stands, a consensus of analysts holds that Cardinal Health has an overall rating of “Hold,” with a consensus price target of $94.69, according to data sourced from MarketBeat.com.